Latest News

Novavax’s Revenue Falls Short. Management Expects a Surge.


The Covid-19 vaccine maker Novavax expects sales of between $4 billion and $5 billion in 2022, it said Monday as it reported less revenue than expected for the fourth quarter.

The biotech reported revenues of $222 million after the market closed. The consensus call among analysts surveyed by FactSet was for $332 million.

Novavax’s Covid-19…

Lucid slashed its production targets by up to 40%, sending its shares tumbling

Previous article

Lucid Stock Sinks As Tesla Rival Slashes 2022 Production Outlook

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News